AR and breast cancer: The treatment effect for BCFI was suggestively stronger among AR− breast cancers (HR[Let.:Tam.] = 0.39, 95% CI 0.21–0.72, p = 0.002) than among AR+ breast cancers (HR[Let.:Tam.] = 0.63, 95% CI 0.47–0.85, p = 0.003), though this difference was not statistically significant (p-heterogeneity = 0.16).